Seres Therapeutics Oral Microbiome Product SER-109 for Recurrent C. Difficile Infection Meets Trial Endpoint
- SER-109 demonstrated a highly statistically significant 30.2% absolute reduction in the rate of C. difficile infection recurrence compared to placebo.
- Efficacy results Support BLA filing as a single pivotal trial.
- The Company will meet with the FDA to discuss filing for product approval as soon as possible.
- Positive SER-109 Phase 3 data provide validation for the Seres microbiome therapeutics platform and further development of its pipeline of product candidates.
- SER-109 was . . .
This content is for paid subscribers.Impacting News August 10, 2020
